Jim Cramer's Mad Dash: Celgene and Morgan Stanley Still Have Upside

NEW YORK (TheStreet) -- Shares of Celgene (CELG) are higher on Wednesday, after posting positive gains on Tuesday when many other stocks saw losses. Jim Cramer attributed these gains to the Food and Drug Administration's approval of the company's psoriasis treatment, which occurred Tuesday. 

Must Read: 10 Stocks Carl Icahn Loves in 2014

On CNBC's "Cramer's Mad Dash" segment, Cramer, the co-manager of the Action Alerts PLUS portfolio, added that the company's work in treating breast cancer and pancreatic cancer is also a positive. 

The company could also emerge with an important arthritis treatment in the future, and "Celgene is not done going higher," he said. 

Turning to Morgan Stanley (MS) , the stock was downgraded by J.P. Morgan. The analyst suggests that the stock is expensive and that UBS AG (UBS) is more attractive. 

Cramer disagreed with the call, saying he likes Morgan Stanley. The company has a "great business" and the stock still has upside, he concluded.

Must Read: Facebook's Media Planning Tool Is Like Giving Money to Murdoch, WPP Says


-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Bank Stocks Move Higher as Fed Decides to Start Unwinding Balance Sheet

Bank Stocks Move Higher Ahead of Federal Reserve Meeting

Morgan Stanley Is Using Snapchat to Recruit College Students and Make Them Rich

WeWork Claims Work as a Concept in Suit Against Chinese 'Copycat'

Citi Trading Revenue May Dive 15% as Goldman Cites 'Challenging' Bond Market